LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance

Yiming Wei and Zhaoming Li*

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Although PD-1 blockade therapy has been promising in cancer treatment, only 4% (pancreatic cancer) to 70% (melanoma) of patients have a positive response to this blockade therapy, which is one of its important disadvantages. Therefore, it is important to seek out new targets for cancer immunotherapy to improve the overall response rate in patients. Lymphocyte activation gene-3 (LAG-3), an immune checkpoint receptor, is mainly expressed in activated immune cells. LAG-3 maintains the body’s immune homeostasis under physiological conditions while mediating tumour immune escape. Several preclinical and clinical examinations have shown that LAG-3 blockade effectively alleviates the patient’s tolerance to PD-1 immune checkpoint inhibitors. Moreover, the combination of LAG-3 and PD-1 blockade has good clinical efficacy in cancers. Hence, synchronous LAG-3 and PD-1 inhibition may be a potential new strategy for tumour immunotherapy.

Keywords: Lymphocyte Activation Gene-3 (LAG-3), immune checkpoint, drug resistance, Programmed Cell Death 1 (PD-1), immunotherapy

INTRODUCTION

Tumour cells can evade the recognition and killing of the immune system of the body with the help of immune checkpoint receptors (1). Thus, blocking immune checkpoint receptors might be a widely effective method of tumor immunotherapy. Currently, although anti-PD-1/PD-L1 antibodies (2) are relatively mature, similar to anti-CTLA4 antibodies, the overall response rate is low in patients because of drug resistance (3, 4). Therefore, finding new tumour immunotherapy targets is urgent. As a new immune checkpoint receptor, LAG-3 plays a vital role in immune homeostasis maintenance and tumour immune escape and is widely present in various activated immune cells (5, 6). The combination of PD-1 and LAG-3 blockade may be a new treatment for drug-resistant patients.

LAG-3 EXPRESSION AND LIGAND

As a type I transmembrane protein, the LAG-3 molecule contains three domains: a transmembrane domain, an extracellular domain, and an intracellular domain. Four immunoglobulin superfamily domains constitute the extracellular domain of the LAG-3 molecule, which binds to its ligand. There are three parts of the transmembrane domain and intracellular domain: the highly conserved...
KIEELE motif (7), the potential serine phosphorylation site S454, and the glutamate-proline-rich sequence. The glutamate-proline rich sequence is also known as the EP repeated sequence and is closely related to the signal transduction of the intracellular region (8).

LAG-3 is expressed widely on different cells: (i) T-cell subpopulations including activated CD4+ T helper cells (Th) and cytotoxic CD8+ T cells (CTL) (9–12). T-cell activation is a necessary condition for LAG-3 expression on T cell subpopulations (13). The LAG-3 level is closely associated with the expression levels of IL-2, IL-7, and IL-12 (14). Additionally, activated CD4+ effector T cells have been shown to express LAG-3, especially on activated natural regulatory T cells (nTregs) and inducible T-regulatory cells (iTregs) (15). (ii) Natural killer (NK) cells and invariant NKT cells (16). (iii) LAG-3+CD138hi plasma cells or regulatory B cells (Bregs), which suppress the immune system through upregulation of IL-10 expression (17). (iv) Other cells, such as plasmacytoid dendritic cells (pDC) and neuronal cells, which do not belong to the lymphocyte lineage (18).

As a typical ligand of LAG-3, MHC-II interacts with LAG-3 through the domain of D1 (19). LAG-3 has a higher affinity for MHC-II than CD4 molecules (20). Significantly, LAG-3 may be cleaved by metalloproteases and release a soluble form of LAG-3 (sLAG-3) (21). It remains unclear whether sLAG-3 has the same high affinity for MHC-II as LAG-3. A previous study showed that MHC-II signalling induced specifically by sLAG-3 severely impaired the differentiation of monocytes (22). In contrast, another study showed that naturally cleaved sLAG-3 does not specifically bind with MHC-II, and only the cell surface LAG-3 dimer or the dimeric LAG-3 Ig fusion protein possesses a high affinity for MHC-II (21). The function and mechanism of sLAG-3 remain to be further explored. LAG-3 negatively modulates T-cell activation and the production of related cytokines by transmitting blocking signals via its cytoplasmic domain (23). Studies have shown that the combination of LAG-3 and MHC-II contributes to avoiding apoptosis of tumour cells and promoting tumour-specific CD4+ T-cell recruitment but reduces the response of CD8+ T cells (7, 13, 23–27). As the second ligand of LAG-3, galectin-3 (Gal-3) shows high expression in multiple cancer cells and activated T lymphocytes and modulates T-cell activation. The cell toxicity of CD8+ T cells can be inhibited by binding to LAG-3 (28, 29). Additionally, fibrinogen-like protein 1 (FGL1), produced by the liver, is a recently identified ligand of LAG-3 (30). As one member of the fibrinogen family, FGL1 mutes antigen-specific T cells by binding to LAG-3 (31). The expression of FGL1 is related to IL-6 via JAK2/STAT3 signalling (32). Studies have shown that FGL1 is abundantly secreted in multiple cancers, including lung cancer, prostate cancer, melanoma, and colorectal cancer (33).

**THE IMMUNOSUPPRESSIVE FUNCTION OF LAG-3**

The interplay between MHC-II and LAG-3 can lower the growth capacity of CD4+ T cells and the secretion of cytokines (13). Moreover, the addition of LAG-3 antibodies can reestablish the activity of CD4+ T cells (34). LAG-3 does not bind to all MHC-II molecules but selectively recognizes and combines antigen peptide-MHC-II complexes (pMHC-II) and controls the pMHC-II-mediated CD4+ T-cell response (35). It has been proven that LAG-3 is an independent negative regulator and that there is no competitive relationship with other regulatory molecules, such as CD4 (35). Experiments have shown that LAG-3 restrains CD4+ T-cell functions by directly transmitting inhibitory signals through the intracellular region but does not block the interaction between CD4-MHC-II or TCR-MHC-II (8, 23, 35).

The activity of CD8+ T cells was higher in LAG-3 knockout (KO) mice than in wild-type mice. Low-level LAG-3 expression was noted in the initial activation of CD8+ T cells, and LAG-3 expression increased after tumour antigen stimulation. Additionally, LAG-3 could significantly inhibit the cytotoxicity of CD8+ T cells (36). In addition, a previous study showed that LAG-3 directly suppressed CD8+ T cells through signal transduction but did not rely on the interaction between CD4+ T cells and MHC-II (35).

Treg cells, including nTreg and iTreg cells, negatively regulate immunity and can decrease the activity of T cells. LAG-3 was capable of inducing the activation of Treg cells and activating their immunosuppressive function (15, 37). LAG-3 is expressed on both activated natural Tregs (nTregs) and induced CD4+ FoxP3+ Treg (iTreg) cells (15). The addition of LAG-3 antibodies can significantly control the activity of Treg cells. Compared with wild-type mice, the negative regulatory function of nTreg cells was significantly downregulated in LAG-3 KO mice (15, 38, 39).

Although the LAG-3 inhibition-induced signalling pathway remains unclear, several studies have discussed this issue. Experiments have shown that LAG-3 is highly correlated with CD3 and that the cross-linking of these two molecules can block the proliferation of T cells, cytokine production, and calcium production (Figure 1). LAG-3 may downregulate the immune response by interfering with TCR signal-transduction (40). Furthermore, the inhibition of LAG-3 in effector CD4+ T cells occurs in a KIEELE motif-dependent manner (23). LAG-3 may transduce two independent inhibitory signals through the KIEELE motif and the FSAL motif in the EP repeat sequence. Both the FSAL motif and KIEELE motif are key points in LAG-3-induced signalling pathways (8). However, how these motifs regulate the TCR response and downstream molecules is still unclear.

**LAG-3 AND TUMOUR IMMUNITY**

MHC-II and FGL-1, as ligands of LAG-3, are related to LAG-3-mediated tumour immune escape (19, 20, 41). MHC-II recruits CD4+ T cells and enhances antitumour immunity in the early stage of tumorigenesis. The activity and expression level of the LAG-3 molecule increases on the surface of TIL cells with the development of tumours. After binding to MHC-II, LAG-3-induced antitumour immunity turns into immunosuppression. For example, MHC-II-expressing melanoma cells block the functions of tumour-infiltrating CD4+ T cells, thus evading the recognition and killing of the immune system (42). FGL-1 is secreted by the liver (30). Under normal circumstances, the
expression of FGL-1 is low in hepatocytes, and its expression markedly increases when cancers occur (31, 33).

Generally, the LAG-3 molecule detected on T cells is regarded as a marker of aggressive progression of cancers. Under the stimulation of tumour antigens, lymphocytes highly express LAG-3 (43, 44). Furthermore, the LAG-3 expression level is obviously related to the survival rate and prognosis of inpatients (45). For example, the number of CTLA-4+LAG-3+ T-cell subsets significantly increased in AML patients, and the production level of LAG-3 was closely related to the classification of patients with AML (46). LAG-3 presented increased expression on the TILs of NSCLC patients (47, 48), and high LAG-3 was also found in nonadenocarcinoma tissues (47). LAG-3 expression in T cells from the peripheral blood of soft tissue sarcoma patients was higher than that in healthy people. LAG-3 is mainly produced and localizes to CD8+ TILs in individuals with soft tissue sarcoma. High LAG-3 expression is related to late-stage disease, high pathological grade, and low survival rates (49). The phenomenon is most obvious in CD8+ TILs in which LAG-3 is highly expressed and combined with its ligand and is detected on the cancer cell surface, leading to the decline or exhaustion of T-cell function and thereby promoting tumour immune escape (36). For example, the overexpression of LAG-3 was detected on CD8+ TILs in ovarian cancer tumour tissues, and cytokine secretion was strongly decreased (50, 51). Although the number of endogenous CD8+ T cells was increased in Hodgkin’s lymphoma patients, their response was low. Moreover, their function was negatively associated with LAG-3 expression on TILs (52–54). The gene expression profile data showed that LAG-3 caused T-cell exhaustion in the tumour microenvironment by cooperating with a variety of inhibitory receptors in patients with melanoma (6, 55, 56).

Chemotherapy affected the expression levels of LAG-3 and PD-1, which ultimately mediated tumour immune escape. The proportion of CD8+LAG3+PD-1+ T cells was significantly higher in patients receiving preoperative paclitaxel plus platinum chemotherapy than in patients receiving surgery alone (57).

**COMBINED ANTI-LAG-3 AND ANTI-PD-1 BLOCKING**

Immune homeostasis is maintained by the balance between costimulatory and inhibitory signals. Increased checkpoint receptors can alleviate antigen-specific T-cell activation, bringing about a proinflammatory response lower than normal circumstances (6). After long-term activation of tumour antigens, checkpoint receptor expression is maintained, which causes effector T cells to enter an “exhaustion” state. Exhausted T cells show a gradual decrease in proliferation capacity and loss of function, including the production of inflammatory cytokines and degranulation (58, 59). Multiple clinical trials have shown that blocking the immune checkpoint PD-1 can significantly improve the clinical treatment effect in malignant tumours by restoring the function of effector T cells. Unfortunately, only a few patients benefit from this therapy because of the development of drug resistance mechanisms within the tumour microenvironment (60–63). The latest data showed that LAG-3 might also be vital in the development of resistance to the curing of PD-1 or PD-L1 by inhibiting the activity and proliferation of CD8+ T cells and increasing the inhibitory activity of Tregs (64–66). LAG-3 can regulate the activity of PD-1+ cells (67). LAG-3 and PD-1 synergistically regulate T-cell function. Combined anti-LAG-3 and anti-PD-1 antibody treatment has shown a strong antitumour effect in mice resistant to single-antibody treatment. Excitingly, there was no obvious evidence of autoimmunity, thus suggesting the possibility of clinical efficacy and safety by combining anti-LAG-3 and anti-PD-1 antibody treatment (36).
| NO. | NCT Number | Title | Tumor | Interventions | Phases |
|-----|------------|-------|-------|---------------|--------|
| 1   | NCT02658981 | A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM | GBM | LAG-3 Antibody; PD-1 Antibody | Phase 1 |
| 2   | NCT03250832 | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors | Solid Tumors | TSR-033; Dostarlimab; mFOLFOX6; FOLFIRI; Bevacizumab | Phase 1 |
| 3   | NCT04080804 | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | HNSCC | Nivolumab; Relatlimab; Ipilimumab | Phase 2 |
| 4   | NCT04140500 | Dose Escalation Study of a PD-1/LAG3 Bischpic Antibody in Patients With Advanced and/or Metastatic Solid Tumors | Solid Tumors | RO7247669 | Phase 1 |
| 5   | NCT01968109 | An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Solid Tumors | Relatlimab; Nivolumab; BMS-986213 | 1/2 |
| 6   | NCT04370704 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCA0N02385 (Anti-LAG-3), and INCA0N02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | Melanoma | INCAGN02385; INCAGN02390; INCMGA00012 | Phase 1/2 |
| 7   | NCT02061761 | Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | Hematologic Neoplasms | BMS-986016; BMS-936558 | Phase 1/2 |
| 8   | NCT03005782 | Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers | Solid Tumors | REGN3767; cemiplimab | Phase 1 |
| 9   | NCT03311412 | Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas | Tumor | Sym021; Sym022; Sym023 | Phase 1 |
| 10  | NCT04618771 | Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies | Solid Tumors | Sym021; Sym022; Sym023 | Phase 1 |
| 11  | NCT03743766 | Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting | Melanoma | Relatlimab; Nivolumab | Phase 2 |
| 12  | NCT04613903 | A Study of EMB-02 in Participants With Advanced Solid Tumors | Solid Tumors | EMB-02 | Phase 1/2 |
| 13  | NCT04785820 | A Study of RO7121661 and RO7247669 Compared With Nivolumab in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | Esophageal Squamous Cell Carcinoma | RO7121661; RO7247669; Nivolumab | Phase 2 |
| 14  | NCT03219638 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | Solid Tumors | MGD013; margetuximab | Phase 1 |
| 15  | NCT03623858 | Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | Chordoma | Nivolumab; Relatlimab | Phase 2 |
| 16  | NCT04634825 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | HNSCC | Enoblituzumab; Retifanlimab; Tebotelimab | Phase 2 |
| 17  | NCT02966548 | Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors | Solid Tumors | Relatlimab; Nivolumab | Phase 1 |
| 18  | NCT03459222 | An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | Solid Tumors | BMS-986205; ipilimumab | Phase 1/2 |
| 19  | NCT03044813 | Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Eosophageal Cancer | Esophageal Cancer | Nivolumab; Relatlimab; Carboplatin; Paclitaxel; Radiation; Radiation | Phase 1 |
| 20  | NCT04326257 | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | HNSCC | Nivolumab; Relatlimab | Phase 2 |
| 21  | NCT04913922 | Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | Acute Myeloid Leukemia | Azacitidine Injection; Nivolumab; Relatlimab | Phase 2 |
| 22  | NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Solid and Hematologic Malignancies | PDR001; LAG525 | Phase 2 |
| 23  | NCT03642067 | Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer | Colorectal Adenocarcinoma | Nivolumab; Relatlimab | Phase 2 |
| 24  | NCT03607890 | Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor | Solid Tumors | Nivolumab; Relatlimab | Phase 2 |
| 25  | NCT04658147 | Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | Nivolumab | Phase 1 |

Abbreviations: Relatlimab, anti-LAG3 antibody; RO7247669, an anti PD-1 and LAG-3 bispecific antibody; BMS-986016, anti-LAG-3; BMS-936558, anti-PD-1 Monoclonal Antibody (Nivolumab); EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3; RO7121661, a PD-1/TIM3 Bispecific Antibody; RO7247669, a PD-1/LAG3 Bispecific Antibody; MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3; PDR001, PD-1 IgG4 antibody; LAG525, LAG-3 antibody; HNSCC, Head and Neck Squamous Cell Carcinoma; GBM, Glioblastoma.
Currently, several molecules targeting LAG-3 are in clinical development (Table 1). Although these molecules were well tolerated, the effect of single-molecule-based therapy was limited. Some animal experiments have implied that LAG-3 might be a potential target in combination with anti-PD-1. (i) Both LAG-3 and PD-1 were observed on T cells in the tumour microenvironment in animal models of mouse MC38 colorectal adenocarcinoma and SalN fibroma. Furthermore, the antitumour efficacy of combined immunotherapy far exceeded that of any single immunotherapy (36). (ii) In a mouse model of ovarian cancer, tumour-infiltrating T cells coexpressed LAG-3 and PD-1. Moreover, LAG-3 and PD-1 blockade upregulated effector T-cell activity, thereby inhibiting tumour growth (51). (iii) Both LAG-3 and PD-1 blockade caused IFN-γ secretion and CD8+ T-cell cytotoxicity upregulation in melanoma (68). (iv) Another study on mouse prostate cancer showed that compared with inhibition of a single target, the combined suppression of PD-1 and LAG-3 markedly improved the antitumour effect of antitumour vaccines (69). (v) Recently, a new fully human anti-LAG-3 therapeutic IgG4 antibody was developed (REGN3767). Furthermore, the combination of REGN3767 and PD-1 antibody showed higher antitumour efficacy and accelerated the production of proinflammatory cytokines in tumour-specific T cells from mouse tumour models established using humanized PD-1xLAG-3 mice. REGN3767 had good pharmacokinetics and toxicity in nonhuman primates, showing good clinical application prospects (70). (vi) In a humanized mouse non-small cell lung cancer model, the LAG-3 antibody TSR-033 enhanced the efficacy of anti-PD-1 monotherapy and increased immune system activation (71). (vii) FS118, a bispecific antibody against PD-L1 and LAG-3, has been confirmed to enhance the activation of T cells in mouse tumour models, bringing about potent antitumour activity (72).

As an IgG4k bispecific DART® molecule that combines LAG-3 and PD-1, tebotelimab could disrupt nonredundant blocking pathways and further restore the function of exhausted T cells. In an open-label, randomized, phase II/III MAHOGANY trial (NCT04082364), tebotelimab reversed PD-1- and LAG-3-mediated inhibitory effects by controlling the interaction with PD-L1/PD-L2 or MHC-II molecules, thereby restoring exhausted T-cell function and enhancing antitumour immunity. Additionally, dual inhibition of PD-1 and LAG-3 improved the effectiveness of HER2 antibodies by increasing the innate and adaptive immune response against HER2-overexpressing cancer cells (73).

Eftilagimod alpha (efti, IMP321 or LAG-3Ig), a soluble LAG-3 protein and MHC-II agonist, activates APC, causing CD8+ T-cell activation. An open-label, multicentre, dose-escalation study in phase I advanced melanoma invalids was performed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the combined efti and PD-1 antibody. Twenty-four melanoma patients received pembrolizumab and subcutaneous efti injections at doses of one mg, six mg, or thirty mg biweekly. The main adverse event of efti was a reaction at the injection site. Dose-limiting toxicity was not reported. The count of activated CD8+ T cells and CD4+ T cells and the IFN-γ expression levels were increased after subcutaneous injection of efti. More importantly, a 33% overall response rate (ORR) was still observed in some patients who were resistant to pembrolizumab. The clinical trial showed that the combination of efti and pembrolizumab is well tolerated and has encouraging antitumour activity (68).

**CONCLUSION AND OUTLOOK**

Although PD-1 blockade has undergone a paradigm shift in multiple malignant cancers, most tumours show a high rate of primary resistance to this drug. Multiple preclinical and clinical data showed that the double-checkpoint inhibition of LAG-3 and PD-1 can be an application for overcoming ICB resistance. Therefore, combined PD-1 and LAG-3 inhibition may be a promising immunotherapy program for cancers. However, the synergistic effects based on anti-PD-1 and anti-LAG-3 need to be further confirmed in different tumours through more clinical trial data.

**AUTHOR CONTRIBUTIONS**

YW and ZL contributed to the conception of the study and wrote the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

Education Department of Henan Province, Key Scientific Research Project plan of Colleges and Universities in Henan Province, Project No.21A320027.

**REFERENCES**

1. Chen DS, Irving BA, Hodi FS. Molecular Pathways: Next-Generation Immunotherapy–Inhibiting Programmed Death-Ligand 1 and Programmed Death-1. *Clin Cancer Res* (2012) 18(24):6580–7. doi: 10.1158/1078-0432.CCR-12-1362

2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. *N Engl J Med* (2012) 366(26):2443–54. doi: 10.1056/NEJMoa1206990

3. van Dijk N, Gil-Jimenez A, Silina K, Hendrickx K, Smit LA, de Feijter JM, et al. Preoperative Ipilimumab Plus Nivolumab in Locoregionally Advanced Urothelial Cancer: The NABUCCO Trial. *Nat Med* (2020) 26(12):1839–44. doi: 10.1038/s41591-020-1085-z

4. Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, et al. Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma: A Randomized Clinical Trial. *JAMA* (2014) 312(17):1744–53. doi: 10.1001/jama.2014.13943

5. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-Inhibitory Receptors With Specialized Functions in Immune Regulation. *Immunity* (2016) 44(5):989–1004. doi: 10.1016/j.immuni.2016.05.001

6. Chihara N, Madi A, Kondo T, Zhang H, Acharya N, Singer M, et al. Induction and Transcriptional Regulation of the Co-Inhibitory Gene Module in T Cells. *Nature* (2018) 558(7710):454–9. doi: 10.1038/s41586-018-0206-z
Workman Cj, Vignali DAA. The CD4-Related Molecule, LAG-3 (CD223), Regulates the Expansion of Activated T Cells. Eur J Immunol (2003) 33(1):247-58. doi: 10.1002/1521-4141(200301)33:1<247::AID-IMMU2255>3.0.CO;2-A

7. Workman Cj, Vignali DAA. The CD4-Related Molecule, LAG-3 (CD223), Regulates the Expansion of Activated T Cells. Eur J Immunol (2003) 33(1):247-58. doi: 10.1002/1521-4141(200301)33:1<247::AID-IMMU2255>3.0.CO;2-A

8. Maeda TK, Sugiura D, Okazaki I-M, Maruhashi T, Okazaki T. Atypical Motifs to CD4. Pequignot E, et al. LAG-3, a Novel Lymphocyte Activation Gene Closely Related to CD2. Cell Mol Immunol (2002) 19(4):405. doi: 10.1002/cmi.2016.23

9. Maeda TK, Sugiura D, Okazaki I-M, Maruhashi T, Okazaki T. Atypical Motifs to CD4. Pequignot E, et al. LAG-3, a Novel Lymphocyte Activation Gene Closely Related to CD2. Cell Mol Immunol (2002) 19(4):405. doi: 10.1002/cmi.2016.23

10. Bae J, Hideshima T, Zhang GL, Zhou J, Keskin DB, Munshi NC, et al. Targeting LAG-3 for Cancer Immunotherapy by Activating Antigen-Specific CD8 T Cell Responses. Acta Pharm Sin B (2010) 10(6):597-603. doi: 10.1016/j.japhs.2010.01.005

11. Bae J, Hideshima T, Zhang GL, Zhou J, Keskin DB, Munshi NC, et al. Targeting LAG-3 for Cancer Immunotherapy by Activating Antigen-Specific CD8 T Cell Responses. Acta Pharm Sin B (2010) 10(6):597-603. doi: 10.1016/j.japhs.2010.01.005

12. Workman Cj, Vignali DAA. Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223). J Immunol (2005) 174(2):688-95. doi: 10.1002/jimm.174.2.688

13. Workman Cj, Vignali DAA. Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223). J Immunol (2005) 174(2):688-95. doi: 10.1002/jimm.174.2.688

14. Sun H, Sun C, Xiao W. Expression Regulation of Co-Inhibitory Molecules on T Cells: Lymphocyte Activation Gene-3 (LAG-3). Cell Mol Immunol (2017) 14(6):529-45. doi: 10.1038/cmi.2016.23

15. Huang C-T, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in Regulatory T Cells. J Exp Med (2004) 201(27):752. doi: 10.1084/jeu.2017.20.3

16. Huang C-T, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in Regulatory T Cells. J Exp Med (2004) 201(27):752. doi: 10.1084/jeu.2017.20.3

17. Lino AC, Dang VD, Lampropoulou V, Pohar J, et al. LAG-3 Regulates the Expansion of Activated T Cells. J Immunol (2019) 203(4):412-23. doi: 10.1155/2019/12326-6066.CIR-14-0150

18. Lino AC, Dang VD, Lampropoulou V, Pohar J, et al. LAG-3 Regulates the Expansion of Activated T Cells. J Immunol (2019) 203(4):412-23. doi: 10.1155/2019/12326-6066.CIR-14-0150

19. Huard B, Prigent P, Bruniquel D, Donini S, El-Tayar N, et al. LAG-3, a Novel Lymphocyte Activation Gene Closely Related to CD4. J Immunol (1995) 155(1):110-18. doi: 10.4049/jimmunol.174.2.688

20. Huard B, Prigent P, Bruniquel D, Donini S, El-Tayar N, et al. LAG-3, a Novel Lymphocyte Activation Gene Closely Related to CD4. J Immunol (1995) 155(1):110-18. doi: 10.4049/jimmunol.174.2.688

21. Marty Pyke R, Thompson WK, Salem RM, Font-Burgada J, Zanetti M, Carter F, et al. The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. Cancer Discovery (2015) 5(1):43-51. doi: 10.1158/2159-8290.CD-14-0863

22. Marty Pyke R, Thompson WK, Salem RM, Font-Burgada J, Zanetti M, Carter F, et al. The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. Cancer Discovery (2015) 5(1):43-51. doi: 10.1158/2159-8290.CD-14-0863

23. Marty Pyke R, Thompson WK, Salem RM, Font-Burgada J, Zanetti M, Carter F, et al. The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. Cancer Discovery (2015) 5(1):43-51. doi: 10.1158/2159-8290.CD-14-0863

24. Marty Pyke R, Thompson WK, Salem RM, Font-Burgada J, Zanetti M, Carter F, et al. The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. Cancer Discovery (2015) 5(1):43-51. doi: 10.1158/2159-8290.CD-14-0863

25. Huard B, Tournier M, Herend T, Triebel F, Faure F. Lymphocyte-Activation Gene 3/Major Histocompatibility Complex Class II Interaction Modulates the Antigenic Response of CD4+ T Lymphocytes. Eur J Immunol (1994) 24(12):3216-21. doi: 10.1002/1521-4141(1994)24:12<3216::AID-IMMU242126>3.0.CO;2-9

26. Huard B, Tournier M, Herend T, Triebel F, Faure F. Lymphocyte-Activation Gene 3/Major Histocompatibility Complex Class II Interaction Modulates the Antigenic Response of CD4+ T Lymphocytes. Eur J Immunol (1994) 24(12):3216-21. doi: 10.1002/1521-4141(1994)24:12<3216::AID-IMMU242126>3.0.CO;2-9
Antigen-Specific CD8+ T Cells in the Tumor Microenvironment. J Exp Med (2017) 214(2):381–400. doi: 10.1084/jem.20160485

Shen J, Postow MA, Adamow M, Arock A, Hannum M, Maher C, et al. LAG-3 Expression on Peripheral Blood Cells Identifies Patients With Poorer Outcomes After Immune Checkpoint Blockade. Sci Transl Med (2021) 13 (608):eabf5107. doi: 10.1126/scitranslmed.aabf5107

Chen C, Liang C, Wang S, Chio CL, Zhang Y, Zeng C, et al. Expression Patterns of Immune Checkpoints in Acute Myeloid Leukemia. J Hematol Oncol (2020) 13(1):28. doi: 10.1186/s13045-020-00853-x

He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, et al. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship With PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol (2017) 12 (5):814–23. doi: 10.1016/j.jtho.2017.01.019

Datar I, Sammann MF, Wang J, Henick BS, Choi J, Badri T, et al. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multivariate Single-Cell Analysis. Clin Cancer Res (2019) 25(15):4663–73. doi: 10.1158/1078-0432.CCR-18-4142

Que Y, Fang Z, Guan Y, Xiao W, Xu B, Zhao J, et al. LAG-3 Expression on Tumor-Infiltrating T Cells in Soft Tissue Sarcoma Correlates With Poor Survival. Cancer Biol Med (2019) 16(2):331–40. doi: 10.20892/j.issn.2095-3941.2018.0306

Matsuizaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller T, Cavailler T, et al. Tumor-Infiltrating NY-ESO-1-Specific CD8+ T Cells Are Negatively Regulated by LAG-3 and PD-1 in Human Ovarian Cancer. Proc Natl Acad Sci USA (2010) 107(7):785–80. doi: 10.1073/pnas.100345107

Huang R-Y, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 Co-Inhibitory Molecules Collaborate to Limit CD8+ T Cell Signaling and Dampen Antitumor Immunity in a Murine Ovarian Cancer Model. Oncotarget (2015) 6(29):27539–77. doi: 10.18632/oncotarget.4751

Gandhi MK, Lambley E, Duraiswamy J, Du A, Smith C, Elliott S, et al. Expression of LAG-3 by Tumor-Infiltrating Lymphocytes is Coincident With the Suppression of Latent Membrane Antigen-Specific CD8+ T-Cell Function in Hodgkin Lymphoma Patients. Blood (2006) 108(7):2280–9. doi: 10.1182/blood-2006-04-15164

El Halabi L, Adam J, Gravelle P, Marty V, Danu A, Lazarovic J, et al. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk (2021) 21 (4):257–66.63. doi: 10.1016/j.clml.2020.11.009

El Halabi L, Adam J, Marty V, Bosq J, Lazarovic J, Danu A, et al. Strong Expression of the Immune Checkpoint Regulators LAG3 and Tim3 in Hodgkin Lymphoma. Blood (2016) 128(22):2952–. doi: 10.1182/blood.V2018.22.2952

Khanna N, Nilsson LM, Mitra S, Alsever R, Price-Troska T, Jalali S, et al. Metalloprotease-Mediated LAG3 Shedding. Sci Immunol (2020) 5(49):eabc278. doi: 10.1126/sciimmunol.abc278

Atkinson V, Khattak A, Haydon A, Eastgate M, Roy A, Prithviraj P, et al. Eftilagimod Alpha, a Soluble Lymphocyte Activation Gene-3 (LAG-3) Protein Plus Pembrolizumab in Patients With Metastatic Melanoma. J Immunother Cancer (2020) 8(2):e001681. doi: 10.1136/jitc-2020-001681

Zahn CD, Moseman JE, Delmastro LE, G Mcneel D, PD-1 and LAG-3 Blockade Improve Anti-Tumor Vaccine Efficacy. Oncimunology (2021) 10 (1):1912892. doi: 10.1080/2162402X.2021.1912892

Burova E, Herrmann A, Dju I, Ullman E, Halasz G, Potocky T, et al. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination With the Anti-PD-1 Antibody Cemiplimub in Human - Knockin Mice. Mel Cancer Ther (2019) 18(11):2051–62. doi: 10.1158/1355-7163.MCT-18-1376

Frasers St, Postow MA, Adamow M, Arock A, Hannum M, Maher C, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 373(1):23–34. doi: 10.1056/NEJMoa1504080

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab After Chemoradiation therapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med (2017) 377(20):1919–29. doi: 10.1056/NEJMoa1709937

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LR, et al. Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade. Science (2017) 357(6349):409–13. doi: 10.1126/science.aan6733

Andrews LP, Somasundaram A, Moskowitz JM, Szmyczak-Workman AL, Liu C, Cillo AR, et al. Resistance to PD1 Blockade in the Absence of Metalloprotease-Mediated LAG3 Shedding. Sci Immunol (2020) 5(49):eabc278. doi: 10.1126/sciimmunol.abc278

Oncogenesis (2017) 8(2):e001681. doi: 10.1136/jitc-2020-001681

Mohler M, et al. MAHOGANY: Margetuximab Combination in HER2+ Unresectable/Metastatic Breast Cancer. J Clin Oncol (2020) 28(13):3036–45. doi: 10.1158/1078-0432.CCR-17-2257

Chen Z, Huang Y, Hu Z, Zhao M, Bian Y, Chen Z, et al. Dissecting the Single-Cell Transcriptome Network in Patients With Esophageal Squamous Cell Carcinoma Receiving Operative Paclitaxel Plus Platinum Chemotherapy. Oncogenesis (2021) 10(10):71. doi: 10.3103/s147389-021-00359-2

60. Yang Z-Z, Kim HJ, Villasboas JC, Chen Y-P, Price-Troska T, Jalali S, et al. Expression of LAG-3 Defines Exhaustion of Intratumoral PD-1 T Cells and Correlates With Poor Outcome in Follicular Lymphoma. Oncotarget (2017) 8 (37):e14125–39. doi: 10.18632/oncotarget.18251

61. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 373(1):23–34. doi: 10.1056/NEJMoa1504080

62. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab After Chemoradiation therapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med (2017) 377(20):1919–29. doi: 10.1056/NEJMoa1709937

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright 2022 Wei and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.